Society for Immunotherapy of Cancer (SITC)
Andrea Kunz is an experienced professional in the fields of publishing and education within cancer immunotherapy and the arts. Serving as the Managing Editor for the Journal for Immunotherapy of Cancer at the Society for Immunotherapy of Cancer since April 2013, Andrea advises on journal policies and strategic direction alongside the Editorial Board. Previously, Andrea held the position of Director of Education Programs, developing continuing education opportunities for researchers and clinicians in immunotherapy. Prior to this, Andrea was the Executive Director of The Wisconsin Philharmonic, managing a $300k annual budget and leading a successful rebranding initiative. Educational credentials include a Bachelor of Science in Music Business and Economics from Carroll University.
This person is not in any offices
Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. sitc_log_color.png Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Currently, SITC has more than 2,000 members who represent 22 medical specialties in 42 countries around the world. Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.